Focusing on Hematological Malignancies

By E. Roy Berger, MD, FACP
Published: Tuesday, Jun 22, 2010
Click here to view as PDF.

Reporting from the American Society of Hematology

As this publication evolves and grows, we're finding that our readers value our coverage of important oncology meetings. Often, data is released at these meetings that can directly impact our practices and the way we treat patients. With this in mind, this month we report on the American Society of Hematology’s (ASH) 49th Annual Meeting, which took place in Atlanta. This meeting provides a forum for hematologists and oncologists from around the world to convene and discuss critical issues in hematology.

ASH offers a global perspective, from practical issues to cutting-edge research. Our pages this month provide summary coverage of meeting highlights, primarily focusing on notable research breakthroughs relating to hematological malignancies, including advances in multiple myeloma, leukemia, and lymphoma. Perhaps no area has garnered more attention (and excitement) than the research being conducted in multiple myeloma. The landscape of treatment in multiple myeloma continues to evolve as results accumulate from trials of conventional and new therapies and from studies on risk factors and side effects. In this issue, we highlight some of the more significant studies presented at ASH.

Our regular columns—Global Reports, Clinical Trial Reports, Physicians’ Financial News, and Reimbursement and Managed Care—also appear in this issue. As with our meeting highlights and news items, these departments provide reports specifically for the community-based oncologist. We hope you find this information useful and look forward to hearing from you.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Bridging the Gaps Around Oncology Biosimilars: Assessing the Potential Impact of Emerging Agents to PracticeSep 29, 20181.5
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x